23 results on '"Puig-Davi, Arnau"'
Search Results
2. A randomized clinical trial to evaluate the efficacy of cognitive rehabilitation and music therapy in mild cognitive impairment in Huntington’s disease
- Author
-
Moreu-Valls, Andrea, Puig-Davi, Arnau, Martinez-Horta, Saul, Kulisevsky, Gabriel, Sampedro, Frederic, Perez-Perez, Jesus, Horta-Barba, Andrea, Olmedo-Saura, Gonzalo, Pagonabarraga, Javier, and Kulisevsky, Jaime
- Published
- 2025
- Full Text
- View/download PDF
3. Measuring cognitive impairment and monitoring cognitive decline in Huntington’s disease: a comparison of assessment instruments
- Author
-
Horta-Barba, Andrea, Martinez-Horta, Saul, Pérez-Pérez, Jesús, Puig-Davi, Arnau, de Lucia, Natascia, de Michele, Giuseppe, Salvatore, Elena, Kehrer, Stefanie, Priller, Josef, Migliore, Simone, Squitieri, Ferdinando, Castaldo, Anna, Mariotti, Caterina, Mañanes, Veronica, Lopez-Sendon, Jose Luis, Rodriguez, Noelia, Martinez-Descals, Asunción, Júlio, Filipa, Januário, Cristina, Delussi, Marianna, de Tommaso, Marina, Noguera, Sandra, Ruiz-Idiago, Jesús, Sitek, Emilia J., Wallner, Renata, Nuzzi, Angela, Pagonabarraga, Javier, and Kulisevsky, Jaime
- Published
- 2023
- Full Text
- View/download PDF
4. Plasma TDP-43 Reflects Cortical Neurodegeneration and Correlates with Neuropsychiatric Symptoms in Huntington’s Disease
- Author
-
Sampedro, Frederic, Martínez-Horta, Saul, Pérez-Pérez, Jesus, Pérez-González, Rocío, Horta-Barba, Andrea, Campolongo, Antonia, Izquierdo, Cristina, Aracil-Bolaños, Ignacio, Rivas, Elisa, Puig-Davi, Arnau, Pagonabarraga, Javier, Gómez-Ansón, Beatriz, and Kulisevsky, Jaime
- Published
- 2022
- Full Text
- View/download PDF
5. A randomized clinical trial of candesartan for cognitive impairment in Parkinson's disease
- Author
-
Kulisevsky, Jaime, Martínez-Horta, Saul, Campolongo, Antonia, Pascual-Sedano, Berta, Marín-Lahoz, Juan, Bejr-kasem, Helena, Labandeira-Garcia, Jose L., Lanciego, Jose L., Puig-Davi, Arnau, Horta-Barba, Andrea, Pagonabarraga, Javier, and Rodríguez-Antigüedad, Jon
- Published
- 2023
- Full Text
- View/download PDF
6. Cortical macro and microstructural correlates of cognitive and neuropsychiatric symptoms in Parkinson’s disease
- Author
-
Sampedro, Frederic, Puig-Davi, Arnau, Martinez-Horta, Saul, Pagonabarraga, Javier, Horta-Barba, Andrea, Aracil-Bolaños, Ignacio, and Kulisevsky, Jaime
- Published
- 2023
- Full Text
- View/download PDF
7. Dissociable contribution of plasma NfL and p-tau181 to cognitive impairment in Parkinson's disease
- Author
-
Pagonabarraga, Javier, Pérez-González, Rocío, Bejr-kasem, Helena, Marín-Lahoz, Juan, Horta-Barba, Andrea, Martinez-Horta, Saul, Aracil-Bolaños, Ignacio, Sampedro, Frederic, Campolongo, Antonia, Rivas, Elisa, Puig-Davi, Arnau, Ruiz-Barrios, I., Pérez-Pérez, Jesús, Pascual-Sedano, Berta, and Kulisevsky, Jaime
- Published
- 2022
- Full Text
- View/download PDF
8. Measuring the functional impact of cognitive impairment in Huntington’s disease
- Author
-
Horta-Barba, Andrea, Martínez-Horta, Saül, Pérez-Pérez, Jesus, Sampedro, Frederic, Puig-Davi, Arnau, Pagonabarraga, Javier, and Kulisevsky, Jaime
- Published
- 2022
- Full Text
- View/download PDF
9. Increased homocysteine levels correlate with cortical structural damage in Parkinson's disease
- Author
-
Sampedro, Frederic, Martínez-Horta, Saul, Horta-Barba, Andrea, Grothe, Michel J., Labrador-Espinosa, Miguel A., Jesús, Silvia, Adarmes-Gómez, Astrid, Carrillo, Fátima, Puig-Davi, Arnau, Lora, Florinda Roldán, Barberá, Miquel Aguilar, Pastor, Pau, Arroyo, Sonia Escalante, Vila, Berta Solano, Foraster, Anna Cots, Martínez, Javier Ruiz, Padilla, Francisco Carrillo, Morlans, Mercedes Pueyo, Aramburu, Isabel González, Ceberio, Jon Infante, Vara, Jorge Hernández, de Fábregues-Boixar, Oriol, de Deus Fonticoba, Teresa, Ávila, Asunción, Martínez-Castrillo, Juan Carlos, Bejr-Kasem, Helena, Campolongo, Antonia, Pascual-Sedano, Berta, Martínez-Martín, Pablo, Santos-García, Diego, Mir, Pablo, and Kulisevsky, Jaime
- Published
- 2022
- Full Text
- View/download PDF
10. Prediction of Cognitive Heterogeneity in Parkinson's Disease: A 4‐Year Longitudinal Study Using Clinical, Neuroimaging, Biological and Electrophysiological Biomarkers.
- Author
-
Puig‐Davi, Arnau, Martinez‐Horta, Saul, Pérez‐Carasol, Laura, Horta‐Barba, Andrea, Ruiz‐Barrio, Iñigo, Aracil‐Bolaños, Ignacio, Pérez‐González, Rocío, Rivas‐Asensio, Elisa, Sampedro, Frederic, Campolongo, Antonia, Pagonabarraga, Javier, and Kulisevsky, Jaime
- Subjects
- *
MILD cognitive impairment , *MAGNETIC resonance imaging , *PARKINSON'S disease , *POWER density , *COGNITION disorders - Abstract
Objective: Cognitive impairment in Parkinson's disease (PD) can show a very heterogeneous trajectory among patients. Here, we explored the mechanisms involved in the expression and prediction of different cognitive phenotypes over 4 years. Methods: In 2 independent cohorts (total n = 475), we performed a cluster analysis to identify trajectories of cognitive progression. Baseline and longitudinal level II neuropsychological assessments were conducted, and baseline structural magnetic resonance imaging, resting electroencephalogram and neurofilament light chain plasma quantification were carried out. Linear mixed‐effects models were used to study longitudinal changes. Risk of mild cognitive impairment and dementia were estimated using multivariable hazard regression. Spectral power density from the electroencephalogram at baseline and source localization were computed. Results: Two cognitive trajectories were identified. Cluster 1 presented stability (PD‐Stable) over time, whereas cluster 2 showed progressive cognitive decline (PD‐Progressors). The PD‐Progressors group showed an increased risk for evolving to PD mild cognitive impairment (HR 2.09; 95% CI 1.11–3.95) and a marked risk for dementia (HR 4.87; 95% CI 1.34–17.76), associated with progressive worsening in posterior‐cortical‐dependent cognitive processes. Both clusters showed equivalent clinical and sociodemographic characteristics, structural magnetic resonance imaging, and neurofilament light chain levels at baseline. Conversely, the PD‐Progressors group showed a fronto‐temporo‐occipital and parietal slow‐wave power density increase, that was in turn related to worsening at 2 and 4 years of follow‐up in different cognitive measures. Interpretation: In the absence of differences in baseline cognitive function and typical markers of neurodegeneration, the further development of an aggressive cognitive decline in PD is associated with increased slow‐wave power density and with a different profile of worsening in several posterior‐cortical‐dependent tasks. ANN NEUROL 2024;96:981–993 [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Skin Tau Quantification as a Novel Biomarker in Huntington's Disease.
- Author
-
Ruiz‐Barrio, Iñigo, Vázquez‐Oliver, Anna, Puig‐Davi, Arnau, Rivas‐Asensio, Elisa, Perez‐Perez, Jesus, Fernandez‐Vizuete, Cristina, Horta‐Barba, Andrea, Olmedo‐Saura, Gonzalo, Salvat‐Rovira, Nil, Sampedro, Frederic, Vacchi, Elena, Melli, Giorgia, Pagonabarraga, Javier, Kulisevsky, Jaime, and Martinez‐Horta, Saul
- Abstract
Background: Emerging research implicates tau protein dysregulation in the pathophysiology of Huntington's disease. Objective: This study investigated skin tau quantification as a potential biomarker for Huntington's disease and its correlation with disease burden outcomes. Methods: In this cross‐sectional study, we measured skin tau levels using enzyme‐linked immunosorbent assay in 23 Huntington's disease mutations carriers and eight control subjects, examining group discrimination, correlations with genetic markers, clinical assessments, and neuroimaging data. Brain atrophy was quantified by both volumetric measurements from brain segmentation and a voxel‐based morphometry approach. Results: Our findings showed elevated skin tau levels in manifest Huntington's disease compared with premanifest and healthy controls. These levels correlated with CAG repeat length, CAG‐Age‐Product score, composite Unified Huntington's Disease Rating Scale Total Motor Score, cognitive assessments, and disease‐related cortical and subcortical volumes, all independent of age and gender. Using skin tau levels in cluster analysis along with genetic and clinical measures led to improved subject stratification, providing enhanced distinction and validity of clusters. Conclusions: This study not only confirms the feasibility of skin tau quantification in Huntington's disease but also establishes its potential as a biomarker for enhancing group classification and assessing disease severity across the Huntington's disease spectrum, opening new directions in biomarker research. © 2024 International Parkinson and Movement Disorder Society. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. Cognitive phenotype and neurodegeneration associated with Tau in Huntington's disease
- Author
-
Martinez‐Horta, Saul, primary, Perez‐Perez, Jesús, additional, Perez‐Gonzalez, Rocío, additional, Sampedro, Frederic, additional, Horta‐Barba, Andrea, additional, Campolongo, Antonia, additional, Rivas‐Asensio, Elisa, additional, Puig‐Davi, Arnau, additional, Pagonabarraga, Javier, additional, and Kulisevsky, Jaime, additional
- Published
- 2024
- Full Text
- View/download PDF
13. Baseline Large‐Scale Network Dynamics Associated with Disease Progression in Huntington's Disease
- Author
-
Aracil‐Bolaños, Ignacio, primary, Pérez‐Pérez, Jesús, additional, Martínez‐Horta, Saül, additional, Horta‐Barba, Andrea, additional, Puig‐Davi, Arnau, additional, García‐Cornet, Júlia, additional, Olmedo‐Saura, Gonzalo, additional, Campolongo, Antonia, additional, Pagonabarraga, Javier, additional, and Kulisevsky, Jaime, additional
- Published
- 2023
- Full Text
- View/download PDF
14. Clinical and structural brain correlates of hypomimia in early‐stage Parkinson's disease
- Author
-
Sampedro, Frederic, Martínez-Horta, Saul, Horta, Andrea, Grothe, Michael J., Labrador-Espinosa, Miguel A., Jesús, Silvia, Adarmes-Gómez, A. D, Carrillo, Fatima, Puig-Davi, Arnau, Roldan-Lora, Florinda, Aguilar-Barbera, Miquel, Pastor, Pau, Escalante Arroyo, Sonia, Solano Vila, Berta, Cots-Foraster, Anna, Ruiz-Martínez, Javier, Carrillo-Padilla, Francisco, Pueyo-Morlans, Mercedes, Gonzalez-Aramburu, Isabel, Infante-Ceberio, Jon, Hernandez-Vara, Jorge, Fàbregues-Boixar i Nebot, Oriol de, Deus Fonticoba, María Teresa de, Avila, Asuncion, Martínez-Castrillo, Juan Carlos, Bejr-Kasem, Helena, Campolongo, Antonia, Pascual-Sedano, Berta, Martínez-Martín, Pablo, Santos García, Diego, Mir, Pablo, Garcia-Ruiz, Pedro J., Kulisevsky, J., Universitat Autònoma de Barcelona, and Curemos el Párkinson
- Subjects
Parkinson's disease ,Apathy ,Hypomimia ,Brain ,Parkinson Disease ,Non-motor symptoms ,Hypokinesia ,Cross-Sectional Studies ,Neurology ,Humans ,Neuroimage ,Neurology (clinical) ,Neural - Abstract
COPPADIS Study Group., [Background and purpose] Reduced facial expression of emotions is a very frequent symptom of Parkinson's disease (PD) and has been considered part of the motor features of the disease. However, the neural correlates of hypomimia and the relationship between hypomimia and other non-motor symptoms of PD are poorly understood., [Methods] The clinical and structural brain correlates of hypomimia were studied. For this purpose, cross-sectional data from the COPPADIS study database were used. Age, disease duration, levodopa equivalent daily dose, Unified Parkinson's Disease Rating Scale part III (UPDRS-III), severity of apathy and depression and global cognitive status were collected. At the imaging level, analyses based on gray matter volume and cortical thickness were used., [Results] After controlling for multiple confounding variables such as age or disease duration, the severity of hypomimia was shown to be indissociable from the UPDRS-III speech and bradykinesia items and was significantly related to the severity of apathy (β = 0.595; p, [Conclusion] Reduced facial expressivity in PD is related to the severity of symptoms of apathy and is mediated by the dysfunction of brain systems involved in motor control and in the recognition, integration and expression of emotions. Therefore, hypomimia in PD may be conceptualized not exclusively as a motor symptom but as a consequence of a multidimensional deficit leading to a symptom where motor and non-motor aspects converge., Fundación Curemos el Parkinson (https://curemoselparkinson.org/).
- Published
- 2022
- Full Text
- View/download PDF
15. Baseline Large‐Scale Network Dynamics Associated with Disease Progression in Huntington's Disease.
- Author
-
Aracil‐Bolaños, Ignacio, Pérez‐Pérez, Jesús, Martínez‐Horta, Saül, Horta‐Barba, Andrea, Puig‐Davi, Arnau, García‐Cornet, Júlia, Olmedo‐Saura, Gonzalo, Campolongo, Antonia, Pagonabarraga, Javier, and Kulisevsky, Jaime
- Abstract
Background: Huntington's disease (HD) is a genetically determined disease with motor, cognitive, and neuropsychiatric disorders. However, the links between clinical progression and disruptions to dynamics in motor and cognitive large‐scale networks are not well established. Objective: To investigate changes in dynamic and static large‐scale networks using an established tool of disease progression in Huntington's disease, the composite Unified Huntington's Disease Rating Scale (cUHDRS). Methods: Sixty‐four mutation carriers were included. Static and dynamic baseline functional connectivity as well as topological features were correlated to 2‐year follow‐up clinical assessments using the cUHDRS. Results: Decline in cUHDRS scores was associated with higher connectivity between frontal default‐mode and motor networks, whereas higher connectivity in posterior, mainly visuospatial regions was associated with a smaller decline in cUHDRS scores. Conclusions: Structural disruptions in HD were evident both in posterior parietal/occipital and frontal motor regions, with reciprocal increases in functional connectivity. However, although higher visuospatial network connectivity was tied to a smaller cUHDRS decline, increased motor and frontal default‐mode connections were linked to a larger cUHDRS decreases. Therefore, divergent functional compensation mechanisms might be at play in the clinical evolution of HD. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
16. Divergent cognitive trajectories in early stage Huntington's disease: A 3‐year longitudinal study
- Author
-
Martínez‐Horta, Saul, primary, Perez‐Perez, Jesús, additional, Oltra‐Cucarella, Javier, additional, Sampedro, Frederic, additional, Horta‐Barba, Andrea, additional, Puig‐Davi, Arnau, additional, Pagonabarraga, Javier, additional, and Kulisevsky, Jaime, additional
- Published
- 2023
- Full Text
- View/download PDF
17. A Randomized Clinical Trial to Evaluate the Effects of Safinamide on Apathetic Non-demented Patients With Parkinson's Disease
- Author
-
Kulisevsky, Jaime, primary, Martínez-Horta, Saul, additional, Campolongo, Antonia, additional, Pascual-Sedano, Berta, additional, Marín-Lahoz, Juan, additional, Bejr-kasem, Helena, additional, Aracil-Bolaños, Ignacio, additional, Horta-Barba, Andrea, additional, Puig-Davi, Arnau, additional, and Pagonabarraga, Javier, additional
- Published
- 2022
- Full Text
- View/download PDF
18. Measuring the functional impact of cognitive impairment in Huntington's disease
- Author
-
Horta, Andrea, Martinez-Horta, Saul, Pérez-Pérez, Jesús, Sampedro, Frederic, Puig-Davi, Arnau, Pagonabarraga Mora, Javier, Kulisevsky, Jaime, Universitat Autònoma de Barcelona, Horta, Andrea, Martinez-Horta, Saul, Pérez-Pérez, Jesús, Sampedro, Frederic, Puig-Davi, Arnau, Pagonabarraga Mora, Javier, Kulisevsky, Jaime, and Universitat Autònoma de Barcelona
- Abstract
Background: Patients with Huntington's disease (HD) exhibit a variable predominance of cognitive, behavioral and motor symptoms. A specific instrument focusing on the impact of cognitive impairment in HD over functional capacity is lacking. Objective: To address the need for a brief and specifically developed HD questionnaire able to capture functional aspects suspected to be sensitive to cognitive impairment. Methods: We developed and validated the "Huntington's Disease-Cognitive Functional Rating Scale" (HD-CFRS) in 78 symptomatic carriers of the Huntington's disease mutation. We also administered the HD-CFRS to a knowledgeable informant to measure the level of agreement. To explore the association between HD-CFRS scores and participants' cognitive status, we administered objective measures of cognition. Participants were classified as cognitively preserved (HD-NC), as having mild cognitive impairment (HD-MCI), or as having dementia (HD-Dem). Results: The HD-CFRS showed concurrent validity and internal consistency in the three groups. HD carriers and informants in the HD-NC group obtained similar HD-CFRS scores. However, in patients with mild cognitive impairment and dementia, informers reported greater functional impairment than HD participants. The HD-CFRS total score showed strong correlations with measures assessing cognition. Conclusions: These findings support the utility of the HD-CFRS as a brief and reliable instrument to measure functional defects associated with cognitive impairment in HD. We believe this questionnaire could be a useful tool both for clinical practice and research.
- Published
- 2022
19. Increased homocysteine levels correlate with cortical structural damage in Parkinson's disease
- Author
-
Centres de Recerca de Catalunya, Centro Investigación Biomédica en Red Enfermedades Neurodegenerativas (España), Fundació La Marató de TV3, Instituto de Salud Carlos III, European Commission, Universidad de Sevilla, Sampedro, Frederic, Martínez-Horta, Saúl, Horta-Barba, Andrea, Grothe, Michel J., Labrador, Miguel Ángel, Jesús Maestre, Silvia, Adarmes Gómez, A. D., Carrillo, Fátima, Puig-Davi, Arnau, Roldán, Florinda, Aguilar Barberá, Miquel, Pastor, Pau, Escalante, Sonia, Solano Vila, Berta, Cots Foraster, Ana, Ruiz Martínez, Javier, Carrillo Padilla, Francisco, Pueyo Morlans, Mercedes, González-Aramburu, Isabel, Infante, Jon, Hernández-Vara, Jorge, Fábregues-Boixar, Oriol de, Deus Fonticoba, T. de, Ávila, Asunción, Martínez-Castrillo, J. C., Bejr-Kasem, Helena, Campolongo, Antonia, Pascual-Sedano, Berta, COPPADIS Study Group, Martínez-Martín, Pablo, Santos-García, Diego, Mir, Pablo, Kulisevsky, Jaime, Centres de Recerca de Catalunya, Centro Investigación Biomédica en Red Enfermedades Neurodegenerativas (España), Fundació La Marató de TV3, Instituto de Salud Carlos III, European Commission, Universidad de Sevilla, Sampedro, Frederic, Martínez-Horta, Saúl, Horta-Barba, Andrea, Grothe, Michel J., Labrador, Miguel Ángel, Jesús Maestre, Silvia, Adarmes Gómez, A. D., Carrillo, Fátima, Puig-Davi, Arnau, Roldán, Florinda, Aguilar Barberá, Miquel, Pastor, Pau, Escalante, Sonia, Solano Vila, Berta, Cots Foraster, Ana, Ruiz Martínez, Javier, Carrillo Padilla, Francisco, Pueyo Morlans, Mercedes, González-Aramburu, Isabel, Infante, Jon, Hernández-Vara, Jorge, Fábregues-Boixar, Oriol de, Deus Fonticoba, T. de, Ávila, Asunción, Martínez-Castrillo, J. C., Bejr-Kasem, Helena, Campolongo, Antonia, Pascual-Sedano, Berta, COPPADIS Study Group, Martínez-Martín, Pablo, Santos-García, Diego, Mir, Pablo, and Kulisevsky, Jaime
- Abstract
[Background] Blood homocysteine appears to be increased in Parkinson's disease (PD) and may play a role in the development and progression of this disorder. However, the specific contribution of abnormal homocysteine levels to cortical degeneration in PD remains elusive., [Objective] To characterize the cortical structural correlates of homocysteine levels in PD., [Methods] From the COPPADIS cohort, we identified a subset of PD patients and healthy controls (HC) with available homocysteine and imaging data. Surface-based vertex-wise multiple regression analyses were performed to investigate the cortical macrostructural (cortical thinning) and microstructural (increased intracortical diffusivity) correlates of homocysteine levels in this sample., [Results] A total of 137 PD patients and 43 HC were included. Homocysteine levels were increased in the PD group (t = −2.2, p = 0.03), correlating in turn with cognitive performance (r = −0.2, p = 0.03). Homocysteine in PD was also associated with frontal cortical thinning and, in a subset of patients with available DTI data, with microstructural damage in frontal and posterior-cortical regions (p < 0.05 Monte-Carlo corrected)., [Conclusions] Homocysteine in PD appears to be associated with cognitive performance and structural damage in the cerebral cortex. These findings not only reinforce the presence and importance of cortical degeneration in PD, but also suggest that homocysteine plays a role among the multiple pathological processes thought to be involved in its development.
- Published
- 2022
20. Cognitive and Affective Empathy in Huntington’s Disease
- Author
-
Puig-Davi, Arnau, primary, Martinez-Horta, Saul, additional, Sampedro, Frederic, additional, Horta-Barba, Andrea, additional, Perez-Perez, Jesus, additional, Campolongo, Antonia, additional, Izquierdo-Barrionuevo, Cristina, additional, Pagonabarraga, Javier, additional, Gomez-Anson, Beatriz, additional, and Kulisevsky, Jaime, additional
- Published
- 2021
- Full Text
- View/download PDF
21. Predictors of clinically significant quality of life impairment in Parkinson's disease
- Author
-
Santos García, Diego, de Deus Fonticoba, Teresa, Cores Bartolomé, Carlos, Muñoz, G., Paz González, J. M., Martínez Miró, C., Suárez, E., Jesús, S., Aguilar Barberà, Miquel, Pastor, P., Planellas, L., Cosgaya, Marina, García Caldentey, J., Caballol, Nuria, Legarda, I., Hernández-Vara, Jorge, Cabo-Lopez, Iria, López Manzanares, L., González Aramburu, I., Ávila, Asunción, Catalán, M. J., Nogueira, V., Puente, V., Ruíz de Arcos, M., Borrué, Carmen, Solano Vila, B., Álvarez Sauco, M., Vela, Lydia, Escalante, Sonia, Cubo, Esther, Carrillo Padilla, Francisco, Martínez-Castrillo, Juan Carlos, Sánchez Alonso, P., Alonso Losada, M. G., López Ariztegui, N, Gastón, I., Clavero, P., Kulisevsky, Jaime, Blázquez Estrada, Marta, Seijo, M., Rúiz Martínez, J., Valero, C., Kurtis, M., Fàbregues-Boixar i Nebot, Oriol de, González-Ardura, J, Ordás, C., López Díaz, L. M., McAfee, D., Martinez-Martin, P., Mir, P., Adarmes, D. A., Almeria, Marta, Alonso-Cánovas, Araceli, Alonso Frech, Fernando, Alonso Redondo, Rubén, Álvarez, I., Aneiros Díaz, Á., Arnáiz, S., Arribas, S., Ascunce Vidondo, A., Bernardo Lambrich, N., Bejr-Kasem Marco, Helena, Botí, M. Ángeles, Buongiorno, M. T., Cabello González, C., Cámara, Ana, Canfield Medina, H., Carrillo, F., Casas, E., Cortina Fernández, A., Cots-Foraster, Anna, Crespo Cuevas, Ane Miren, Díez-Fairen, M., Dotor García-Soto, J., Erro, E., Estelrich Peyret, E., Fernández Guillán, N., Gámez, Pedro, Gallego, Miguel, García Campos, C., García Moreno, José Manuel, Gómez Garre, M. P., Gómez Mayordomo, V., González Aloy, J., González García, B., González Palmás, M. J., Toledo, G., Gabriel, R., Golpe Díaz, A., Grau Solá, M., Guardia, G., Horta, Andrea, Idoate Calderón, D., Infante, J., Labandeira, C., Labrador-Espinosa, Miguel A, Lacruz, F., Lage Castro, M., Lastres Gómez, S., López Seoane, B., Lucas del Pozo, S., Macías, Y., Mata, M., Martí Andres, G., Martí, M. J., Meitín, M. T., Menéndez González, M., Méndez del Barrio, C., Miranda Santiago, J., Casado, M., María, I., Moreno Diéguez, A., Novo Amado, A., Novo Ponte, S., Pagonabarraga Mora, Javier, Pareés, I., Pascual-Sedano, Berta María, Pérez Fuertes, A., Pérez Noguera, R., Planas-Ballvé, A., Prats, M. A., Prieto Jurczynska, C., Pueyo Morlans, M., Puig-Davi, Arnau, Redondo Rafales, N., Rodríguez Méndez, L., Rodríguez Pérez, A. B., Roldán, F., Sánchez-Carpintero, M., Sánchez Díez, G., Sánchez Rodríguez, A., Santacruz, P., Segundo Rodríguez, J. C., Sierra Peña, M., Tartari, J. P., Vargas, L., Villanueva, C., Vives-Pastor, B, Villar, M. D., Institut Català de la Salut, [Santos García D, Cores C, Muñoz G, Paz González JM, Martínez Miró C] CHUAC, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain. [de Deus Fonticoba T] CHUF, Complejo Hospitalario Universitario de Ferrol, A Coruña, Spain. [Hernández Vara J, de Fábregues O] Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus, Universidad de Cantabria, AbbVie Pharmaceuticals, Abbott Laboratories, Allergan Foundation, BIAL Foundation, Merz Pharma, UCB Pharma, Zambon, Ministerio de Economía y Competitividad (España), Instituto de Salud Carlos III, European Commission, Junta de Andalucía, Sociedad Andaluza de Neurología, Jacques and Gloria Gossweiler Foundation, Fundación Alicia Koplowitz, and Fundación Mutua Madrileña
- Subjects
Quality of life ,Qualitat de vida--Avaluació ,Parkinson's disease ,Parkinson, Malaltia de - Prognosi ,Nervous System Diseases::Nervous System Diseases::Nervous System Diseases::Neurodegenerative Diseases::Parkinson Disease [DISEASES] ,Article ,humanities ,Environment and Public Health::Public Health::Epidemiologic Measurements::Demography::Health Status::Quality of Life [HEALTH CARE] ,Cellular and Molecular Neuroscience ,enfermedades del sistema nervioso::enfermedades del sistema nervioso::enfermedades del sistema nervioso::enfermedades neurodegenerativas::enfermedad de Parkinson [ENFERMEDADES] ,Neurology ,Pathological Conditions, Signs and Symptoms::Pathologic Processes::Disease Attributes::Disease Progression::Clinical Deterioration [DISEASES] ,Neurology. Diseases of the nervous system ,Neurology (clinical) ,Parkinson, Malaltia de ,RC346-429 ,afecciones patológicas, signos y síntomas::procesos patológicos::atributos de la enfermedad::progresión de la enfermedad::deterioro clínico [ENFERMEDADES] ,Qualitat de vida - Avaluació ,ambiente y salud pública::salud pública::medidas epidemiológicas::demografía::estado de salud::calidad de vida [ATENCIÓN DE SALUD] - Abstract
COPPADIS Study Group., Quality of life (QOL) plays an important role in independent living in Parkinson’s disease (PD) patients, being crucial to know what factors impact QoL throughout the course of the disease. Here we identified predictors of QoL impairment in PD patients from a Spanish cohort. PD patients recruited from 35 centers of Spain from the COPPADIS cohort from January 2016, to November 2017, were followed up during 2 years. Health-related QoL (HRQoL) and global QoL (GQoL) were assessed with the 39-item Parkinson’s disease Questionnaire (PDQ-39) and the EUROHIS-QOL 8-item index (EUROHIS-QOL8), respectively, at baseline (V0) and at 24 months ± 1 month (V2). Clinically significant QoL impairment was defined as presenting an increase (PDQ-39SI) or decrement (EUROHIS-QOL8) at V2 ≥ 10% of the score at baseline (V0). A comparison with a control group was conducted for GQoL. GQoL did not change significantly in PD patients (N = 507; p = 0.686) or in the control group (N = 119; p = 0.192). The mean PDQ-39SI was significantly increased in PD patients (62.7 ± 8.5 years old; 58.8% males; N = 500) by 21.6% (from 16.7 ± 13 to 20.3 ± 16.4; p, Mir P. has received honoraria from AbbVie, Abbott, Allergan, Bial, Merz, UCB and Zambon and have received grants from the Spanish Ministry of Economy and Competitiveness [PI16/01575] co-founded by ISCIII (Subdirección General de Evaluación y Fomento de la Investigación) and by Fondo Europeo de Desarrollo Regional (FEDER), the Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía [CVI-02526, CTS-7685], the Consejería de Salud y Bienestar Social de la Junta de Andalucía [PI-0437-2012, PI-0471-2013], the Sociedad Andaluza de Neurología, the Jacques and Gloria Gossweiler Foundation, the Fundación Alicia Koplowitz, the Fundación Mutua Madrileña.
- Published
- 2021
22. Neuroanatomical and Functional Correlates of Cognitive and Affective Empathy in Young Healthy Adults
- Author
-
Uribe, Carme, primary, Puig-Davi, Arnau, additional, Abos, Alexandra, additional, Baggio, Hugo C., additional, Junque, Carme, additional, and Segura, Barbara, additional
- Published
- 2019
- Full Text
- View/download PDF
23. Correlats neuroanatòmics i diferències de gènere en l’empatia cognitiva i afectiva en una mostra de joves sans
- Author
-
Puig Davi, Arnau and Universitat Ramon Llull. Facultat de Psicologia, Ciències de l’Educació i de l’Esport Blanquerna
- Subjects
Empatia -- TFG ,Psicologia -- TFG ,Joves -- TFG ,Neuropsicologia -- TFG - Abstract
Introducció: L’estudi de l’empatia des de la neurociència i la neuroimatge funcional ha suggerit l’existència de dos circuits diferents: el de l’empatia afectiva i el de l’empatia cognitiva. Ara bé, els correlats neuroanatòmics de l’empatia no són ben coneguts ni hi ha un consens en la literatura en si existeixen diferències de gènere. L’actual treball pretén explorar les diferències de gènere en les diferents escales d’un test d’empatia validat en població espanyola i investigar les diferències neuroanatòmiques entre persones amb alta i baixa empatia. Mètodes: Es varen analitzar imatges per ressonància magnètica potenciades en T1 adquirides amb un aparell de 3-tesla i el Test d’Empatia Cognitiva i Afectiva (TECA) en una mostra de 42 adults sans (22 dones i 20 homes) emparellats per edat, anys d’educació, nivell educatiu, ocupació i estimació de quocient d’intel·ligència. Es va utilitzar un model lineal general amb les dades de gruix cortical per fer comparacions entre grups d’empatia Alta (A) i Mitjana-Baixa (MB). Es van realitzar també correlacions i comparacions grupals amb les parcel·lacions corticals i segmentacions subcorticals. Resultats: En 4 de les 5 escales del test d’empatia es van trobar diferències de gènere. No obstant, no hi havia diferències entre la proporció d’homes i dones entre els grups d’empatia A o MB. En l’escala d’Adopció de Perspectives, el grup d’empatia A tenia un major gruix cortical respecte al de MB en el còrtex prefrontal, el lòbul parietal inferior i en regions occipitals. Les puntuacions en les escales d’empatia cognitiva van correlacionar amb regions frontals i temporals. No es van trobar correlacions ni diferències significatives en cap estructura subcortical excepte en el tàlem dret que tenia major volum en el grup d’empatia A en l’escala d’Estrès Empàtic. Conclusions: El còrtex orbitofrontal i el cingulat són estructures relacionades amb l’empatia cognitiva. El processament empàtic no és diferent entre homes i dones. Background: From a neuroscientific and functional neuroimaging approach, the study of empathy has suggested the existence of two different networks in the empathy construct: the affective empathy and the cognitive empathy. However, neuroanatomic correlates of empathy are not entirely known and there’s no consensus in literature about the existence of gender differences. Current work, aims to explore gender differences in a Spanish validated empathy test scales and to investigate neuroanatomic differences between high empathy and low empathy subjects. Methods: T1-weighted 3-tesla MRI and the Affective Empathy and Cognitive Test (TECA) were analysed in a sample of 42 healthy adults (22 women and 20 men) matched by age, years of education, level of education, occupation and intelligence quotient estimation. A general linear model with cortical thickness data was used to compare the High empathy group (H) and the Medium-Low group (ML). Group comparisons and correlations were also assessed with cortical parcellations and subcortical segmentations. Results: Gender differences were found in 4 out of 5 empathy test scales. However, there were no significant differences between the proportion of men and women in the empathy groups H or ML. In the Perspective Taking scale, the H empathy group showed increased cortical thickness related to the ML empathy group in the prefrontal cortex, the inferior parietal lobule and in occipital regions. Scores from cognitive empathy scales correlated with frontal and temporal regions. No correlations or significant differences were found in any subcortical structure except for the right thalamus that had an increased volume in the H empathy group in the Empathic Stress scale. Conclusions: The orbitofrontal and cingulate cortices are brain structures related to cognitive empathy. Gender was not a key variable in the empathic response.
- Published
- 2018
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.